These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21591319)

  • 41. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits.
    Kee P; Caiazza D; Rye KA; Barrett PH; Morehouse LA; Barter PJ
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):884-90. PubMed ID: 16373610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux.
    Tall AR
    Am J Cardiol; 2009 Nov; 104(10 Suppl):39E-45E. PubMed ID: 19895943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).
    Pahl MV; Ni Z; Sepassi L; Moradi H; Vaziri ND
    Nephrol Dial Transplant; 2009 Aug; 24(8):2541-6. PubMed ID: 19297356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS; Ditmarsch M; Kastelein JJP
    Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
    Rennings AJ; Stalenhoef A
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
    Ferri N; Corsini A; Sirtori CR; Ruscica M
    Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP.
    Maugeais C; Perez A; von der Mark E; Magg C; Pflieger P; Niesor EJ
    Biochim Biophys Acta; 2013 Nov; 1831(11):1644-50. PubMed ID: 23872476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of hepatic HDL-related mRNAs on plasma prebeta HDL in cholesterol-fed rabbits.
    Sugano M; Makino N; Yanaga T
    Artery; 1997; 22(4):182-205. PubMed ID: 9576025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on CETP inhibition.
    Davidson MH
    J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
    Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.